|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
|
DE10100586C1
(de)
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Ziegens
|
|
US7829693B2
(en)
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
|
US7491805B2
(en)
|
2001-05-18 |
2009-02-17 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
|
US7423142B2
(en)
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
|
US8546143B2
(en)
|
2001-01-09 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
|
US20050148530A1
(en)
|
2002-02-20 |
2005-07-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
|
WO2005078097A2
(en)
|
2004-02-10 |
2005-08-25 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID (Multifunctional siNA)
|
|
US20050171040A1
(en)
*
|
2001-05-18 |
2005-08-04 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cholesteryl ester transfer protein (CEPT) gene expression using short interfering nucleic acid (siNA)
|
|
US20050261219A1
(en)
*
|
2001-05-18 |
2005-11-24 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
|
|
US7517864B2
(en)
|
2001-05-18 |
2009-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
|
DE10163098B4
(de)
|
2001-10-12 |
2005-06-02 |
Alnylam Europe Ag |
Verfahren zur Hemmung der Replikation von Viren
|
|
US7745418B2
(en)
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
|
DE10202419A1
(de)
|
2002-01-22 |
2003-08-07 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
|
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
GB0212302D0
(en)
*
|
2002-05-28 |
2002-07-10 |
Isis Innovation |
Method of selecting targets for gene silencing by RNA interference
|
|
GB0212303D0
(en)
*
|
2002-05-28 |
2002-07-10 |
Isis Innovation |
Molecular targetting of IGF-1 receptor
|
|
AU2003260370B2
(en)
|
2002-08-05 |
2008-05-22 |
Silence Therapeutics Gmbh |
Further novel forms of interfering RNA molecules
|
|
WO2004014933A1
(en)
|
2002-08-07 |
2004-02-19 |
University Of Massachusetts |
Compositions for rna interference and methods of use thereof
|
|
CA2500224C
(en)
|
2002-09-25 |
2015-04-28 |
University Of Massachusetts |
In vivo gene silencing by chemically modified and stable sirna
|
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
|
US9827263B2
(en)
|
2002-11-05 |
2017-11-28 |
Ionis Pharmaceuticals, Inc. |
2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
|
|
US8198427B1
(en)
|
2002-11-14 |
2012-06-12 |
Dharmacon, Inc. |
SiRNA targeting catenin, beta-1 (CTNNB1)
|
|
US8163896B1
(en)
|
2002-11-14 |
2012-04-24 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
|
US7619081B2
(en)
|
2002-11-14 |
2009-11-17 |
Dharmacon, Inc. |
siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
|
|
US7977471B2
(en)
|
2002-11-14 |
2011-07-12 |
Dharmacon, Inc. |
siRNA targeting TNFα
|
|
US9839649B2
(en)
|
2002-11-14 |
2017-12-12 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
WO2006006948A2
(en)
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
|
US9719092B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting CNTD2
|
|
US7691998B2
(en)
|
2002-11-14 |
2010-04-06 |
Dharmacon, Inc. |
siRNA targeting nucleoporin 62kDa (Nup62)
|
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
US7655785B1
(en)
|
2002-11-14 |
2010-02-02 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
|
|
EP2305812A3
(en)
|
2002-11-14 |
2012-06-06 |
Dharmacon, Inc. |
Fuctional and hyperfunctional sirna
|
|
US7612196B2
(en)
|
2002-11-14 |
2009-11-03 |
Dharmacon, Inc. |
siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
|
|
US9719094B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting SEC61G
|
|
US9771586B2
(en)
|
2002-11-14 |
2017-09-26 |
Thermo Fisher Scientific Inc. |
RNAi targeting ZNF205
|
|
US7592442B2
(en)
|
2002-11-14 |
2009-09-22 |
Dharmacon, Inc. |
siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
|
|
US7635770B2
(en)
|
2002-11-14 |
2009-12-22 |
Dharmacon, Inc. |
siRNA targeting protein kinase N-3 (PKN-3)
|
|
US7250496B2
(en)
|
2002-11-14 |
2007-07-31 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
|
US10011836B2
(en)
|
2002-11-14 |
2018-07-03 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
US9879266B2
(en)
|
2002-11-14 |
2018-01-30 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
US7951935B2
(en)
|
2002-11-14 |
2011-05-31 |
Dharmacon, Inc. |
siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
|
|
US7790867B2
(en)
|
2002-12-05 |
2010-09-07 |
Rosetta Genomics Inc. |
Vaccinia virus-related nucleic acids and microRNA
|
|
US20070141009A1
(en)
*
|
2003-01-03 |
2007-06-21 |
Shaharyar Khan |
Sirna mediated post-transriptional gene silencing of genes involved in alopecia
|
|
BRPI0407107A
(pt)
*
|
2003-01-31 |
2006-01-24 |
Novartis Ag |
Infra-regulação de gene alvo com complexos de oligoribonucleotìdeo de filamento único e polìmero de polietilenoimina (pei)
|
|
WO2004080406A2
(en)
|
2003-03-07 |
2004-09-23 |
Alnylam Pharmaceuticals |
Therapeutic compositions
|
|
CA2519860C
(en)
|
2003-03-21 |
2018-01-16 |
Santaris Pharma A/S |
Short interfering rna (sirna) analogues
|
|
AU2004227414A1
(en)
*
|
2003-04-03 |
2004-10-21 |
Alnylam Pharmaceuticals |
iRNA conjugates
|
|
RU2005141341A
(ru)
|
2003-05-30 |
2006-06-10 |
Эйдженсис, Инк., Сша (Us) |
Полинуклеотид, родственный антигену стволовых клеток простаты (psca), и кодируемый им белок (пептид), гибридома и трансгенное животное для продуцирования антител, композиция для лечения, профилактики, диагностики и прогноза течения раковых заболеваний на их основе (варианты), способ определения их присутствия в исследуемом образце, способ генерации иммунного ответа, способ доставки цитотоксического или диагностического агента в клетку, способ ингибирования роста раковых клеток с их использованием
|
|
US7541442B2
(en)
|
2003-05-30 |
2009-06-02 |
Agensys, Inc. |
Antibodies and related molecules that bind to PSCA proteins
|
|
US7595379B2
(en)
|
2003-05-30 |
2009-09-29 |
Agensys, Inc. |
Antibodies and related molecules that bind to PSCA proteins
|
|
US7888497B2
(en)
|
2003-08-13 |
2011-02-15 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
|
|
US7294704B2
(en)
|
2003-08-15 |
2007-11-13 |
Diadexus, Inc. |
Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
|
|
CN1845993B
(zh)
|
2003-08-28 |
2010-06-23 |
诺瓦提斯公司 |
具有平端和3＇修饰的干扰rna双链体
|
|
WO2005045035A2
(en)
*
|
2003-10-23 |
2005-05-19 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF NOGO AND NOGO RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
EP1526177A1
(en)
|
2003-10-24 |
2005-04-27 |
Institut Curie |
Nucleic acids useful for triggering tumor cell lethality
|
|
US7476729B2
(en)
|
2003-10-24 |
2009-01-13 |
Institut Curie |
Dbait and uses thereof
|
|
US20050191653A1
(en)
*
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
|
US20070275918A1
(en)
*
|
2003-11-07 |
2007-11-29 |
The Board Of Trustees Of The University Of Illinois |
Induction of Cellular Senescence by Cdk4 Disruption for Tumor Suppression and Regression
|
|
SE0303397D0
(sv)
*
|
2003-12-17 |
2003-12-17 |
Index Pharmaceuticals Ab |
Compounds and method for RNA interference
|
|
JP4755113B2
(ja)
|
2004-01-30 |
2011-08-24 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
線維性状態およびその他の疾患の治療のための、オリゴリボヌクレオチドおよびその使用方法
|
|
EP2123759B1
(en)
*
|
2004-02-06 |
2014-01-15 |
Thermo Fisher Scientific Biosciences Inc. |
Stabilized RNAS as transfection controls and silencing reagents
|
|
AU2005222902B2
(en)
|
2004-03-12 |
2010-06-10 |
Alnylam Pharmaceuticals, Inc. |
iRNA agents targeting VEGF
|
|
CA2560046A1
(en)
*
|
2004-03-16 |
2005-09-22 |
Dnavec Research Inc. |
Methods for suppressing tumor proliferation
|
|
EP1735442A2
(en)
*
|
2004-03-24 |
2006-12-27 |
Oncotherapy Science, Inc. |
Compositions and methods for treating pancreatic cancer
|
|
KR101147147B1
(ko)
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
|
EP2520652B1
(en)
*
|
2004-04-09 |
2015-06-10 |
Genecare Research Institute Co., Ltd |
Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes
|
|
AU2005238034A1
(en)
|
2004-04-23 |
2005-11-10 |
The Trustees Of Columbia University In The City Of New York |
Inhibition of hairless protein mRNA
|
|
WO2005108572A1
(de)
*
|
2004-05-06 |
2005-11-17 |
Medizinische Hochschule Hannover |
Verbindungen und verfahren zur immunsuppression
|
|
US7605250B2
(en)
|
2004-05-12 |
2009-10-20 |
Dharmacon, Inc. |
siRNA targeting cAMP-specific phosphodiesterase 4D
|
|
US7687616B1
(en)
|
2004-05-14 |
2010-03-30 |
Rosetta Genomics Ltd |
Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof
|
|
CA2566519C
(en)
|
2004-05-14 |
2020-04-21 |
Rosetta Genomics Ltd. |
Micrornas and uses thereof
|
|
DE102004025881A1
(de)
|
2004-05-19 |
2006-01-05 |
Beiersdorf Ag |
Oligoribonukleotide zur Beeinflussung des Haarwachstums
|
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
|
US7795419B2
(en)
|
2004-05-26 |
2010-09-14 |
Rosetta Genomics Ltd. |
Viral and viral associated miRNAs and uses thereof
|
|
JP4468989B2
(ja)
|
2004-08-16 |
2010-05-26 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
Ｒｔｐ８０１阻害剤の治療への使用
|
|
HRP20171010T8
(hr)
|
2004-08-23 |
2017-11-03 |
Sylentis S.A.U. |
Liječenje poremećaja očiju koji su karakterizirani povišenim intraokularnim pritiskom pomoću sirnk
|
|
EP2287301A3
(en)
|
2004-08-31 |
2011-11-02 |
Sylentis S.A.U. |
Methods and compositions to inhibit P2X7 receptor expression
|
|
AU2005288522B2
(en)
|
2004-09-28 |
2012-06-28 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
|
|
US20090209619A1
(en)
*
|
2004-10-14 |
2009-08-20 |
Zhiguo Wang |
Depression of herg k+ channel function in mammallan cells and applications to the control of cancer cells division
|
|
US20060253100A1
(en)
|
2004-10-22 |
2006-11-09 |
Medtronic, Inc. |
Systems and Methods to Treat Pain Locally
|
|
WO2006050475A2
(en)
|
2004-11-03 |
2006-05-11 |
Brigham And Women's Hospital, Inc. |
Identification of dysregulated genes in patients with neurological diseases
|
|
KR100780548B1
(ko)
*
|
2004-12-08 |
2007-11-29 |
한국원자력연구원 |
Ｓ-아데노실 메티오닌 디카르복실라제 ｍＲＮＡ에특이적인 작은 간섭 ＲＮＡ 및 그를 유효성분으로포함하는 악성종양 치료제
|
|
AU2011203218B2
(en)
*
|
2004-12-09 |
2013-02-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs
|
|
EP1819365B1
(en)
|
2004-12-09 |
2014-07-02 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs
|
|
EP2316942B1
(en)
*
|
2004-12-22 |
2021-04-21 |
Alnylam Pharmaceuticals, Inc. |
Conserved hbv and hcv sequences useful for gene silencing
|
|
CN101287497B
(zh)
|
2004-12-27 |
2013-03-06 |
赛伦斯治疗公司 |
涂层脂质复合体和它们的用途
|
|
JP2008531037A
(ja)
*
|
2005-03-02 |
2008-08-14 |
ナショナル インスティテュート オブ イミュノロジー |
新規なヌクレオチド配列
|
|
GB0505081D0
(en)
|
2005-03-14 |
2005-04-20 |
Genomica Sau |
Downregulation of interleukin-12 expression by means of rnai technology
|
|
WO2006112239A1
(ja)
|
2005-04-15 |
2006-10-26 |
National University Corporation Tottori University |
ｈＴＥＲＴ発現調節遺伝子
|
|
KR20060119412A
(ko)
*
|
2005-05-20 |
2006-11-24 |
아주대학교산학협력단 |
ＩＬ-6 발현 억제를 위한 ｓｉＲＮＡ 및 이를 함유하는조성물
|
|
US20110125075A1
(en)
*
|
2005-07-15 |
2011-05-26 |
National University Corporation Nagoya University |
Method for control of electroporation apparatus
|
|
US7919583B2
(en)
|
2005-08-08 |
2011-04-05 |
Discovery Genomics, Inc. |
Integration-site directed vector systems
|
|
BRPI0614407A2
(pt)
*
|
2005-08-17 |
2009-08-18 |
Sirna Therapeutics Inc |
molécula de ácido nucleico de filamento duplo, e, composição
|
|
GB0521351D0
(en)
|
2005-10-20 |
2005-11-30 |
Genomica Sau |
Modulation of TRPV expression levels
|
|
GB0521716D0
(en)
|
2005-10-25 |
2005-11-30 |
Genomica Sau |
Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
|
|
WO2007053803A2
(en)
*
|
2005-10-31 |
2007-05-10 |
Centocor, Inc. |
Antagonist of teb4 and methods of use
|
|
US8101741B2
(en)
|
2005-11-02 |
2012-01-24 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
|
KR20080082655A
(ko)
*
|
2005-12-29 |
2008-09-11 |
알콘 리서치, 리미티드 |
안구의 혈관신생 치료용 ＩＧＦ１Ｒ의 ＲＮＡⅰ－매개 억제
|
|
NL2000439C2
(nl)
|
2006-01-20 |
2009-03-16 |
Quark Biotech |
Therapeutische toepassingen van inhibitoren van RTP801.
|
|
US7825099B2
(en)
|
2006-01-20 |
2010-11-02 |
Quark Pharmaceuticals, Inc. |
Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
|
|
US7910566B2
(en)
|
2006-03-09 |
2011-03-22 |
Quark Pharmaceuticals Inc. |
Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
|
|
GB0605337D0
(en)
|
2006-03-17 |
2006-04-26 |
Genomica Sau |
Treatment of CNS conditions
|
|
WO2007107162A2
(en)
|
2006-03-23 |
2007-09-27 |
Santaris Pharma A/S |
Small internally segmented interfering rna
|
|
CA2648132C
(en)
*
|
2006-04-03 |
2019-05-28 |
Santaris Pharma A/S |
Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
|
|
GB0608838D0
(en)
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
|
CN101460624B
(zh)
|
2006-06-08 |
2013-06-05 |
阿明诺化学株式会社 |
具有iNOS的表达控制作用的正义寡核苷酸以及含有其的组合物
|
|
US8399424B2
(en)
|
2006-06-08 |
2013-03-19 |
Amino Up Chemical Co., Ltd |
Method for controlling the amount of gene product, and agent for controlling the amount of gene product
|
|
WO2007141796A2
(en)
|
2006-06-09 |
2007-12-13 |
Quark Pharmaceuticals, Inc. |
Therapeutic uses of inhibitors of rtp801l
|
|
US7915399B2
(en)
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
|
EP2061900A2
(en)
|
2006-08-25 |
2009-05-27 |
Oncotherapy Science, Inc. |
Prognostic markers and therapeutic targets for lung cancer
|
|
US20100034736A1
(en)
*
|
2006-09-07 |
2010-02-11 |
Consejo Superior De Investigaciones Cientificas |
Identification of cancer stem cells using genetic markers
|
|
CA2666657A1
(en)
*
|
2006-10-18 |
2008-04-24 |
Nastech Pharmaceutical Company Inc. |
Nicked or gapped nucleic acid molecules and uses thereof
|
|
JP2010507387A
(ja)
|
2006-10-25 |
2010-03-11 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
新規のｓｉＲＮＡおよびその使用方法
|
|
EP2468887A1
(en)
|
2006-12-13 |
2012-06-27 |
Oncotherapy Science, Inc. |
TTK as tumor marker and therapeutic target for lung cancer
|
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
|
US7872119B2
(en)
|
2007-02-26 |
2011-01-18 |
Quark Pharmaceuticals, Inc. |
Inhibitors of RTP801 and their use in disease treatment
|
|
WO2008109454A2
(en)
*
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting fos gene expression and uses thereof
|
|
WO2008109359A1
(en)
*
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting pdgfr family gene expression and uses thereof
|
|
WO2008109492A1
(en)
*
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting igf1r gene expression and uses thereof
|
|
WO2008109378A2
(en)
*
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting pdgfr gene expression and uses thereof
|
|
US7812002B2
(en)
|
2007-03-21 |
2010-10-12 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
|
|
EP2136788B1
(en)
|
2007-03-30 |
2011-10-26 |
Bind Biosciences, Inc. |
Cancer cell targeting using nanoparticles
|
|
US11078262B2
(en)
|
2007-04-30 |
2021-08-03 |
Allergan, Inc. |
High viscosity macromolecular compositions for treating ocular conditions
|
|
JP5296328B2
(ja)
|
2007-05-09 |
2013-09-25 |
独立行政法人理化学研究所 |
１本鎖環状ｒｎａおよびその製造方法
|
|
WO2009001359A2
(en)
|
2007-06-27 |
2008-12-31 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of pro-apoptotic genes
|
|
US8435510B2
(en)
|
2007-08-08 |
2013-05-07 |
Sutter West Bay Hospitals |
Platelet derived growth factor receptor supports cytomegalovirus infectivity
|
|
US10105441B2
(en)
|
2007-08-16 |
2018-10-23 |
The Schepens Eye Research Institute, Inc. |
Method for inhibiting or reducing dry eye disease by IL-1Ra
|
|
WO2009028521A1
(en)
|
2007-08-24 |
2009-03-05 |
Oncotherapy Science, Inc. |
Pkib and naaladl2 for target genes of prostate cancer therapy and diagnosis
|
|
CN101835893A
(zh)
|
2007-08-24 |
2010-09-15 |
肿瘤疗法科学股份有限公司 |
癌症相关基因cdca5、epha7、stk31和wdhd1
|
|
DK2548962T3
(en)
|
2007-09-19 |
2016-04-11 |
Applied Biosystems Llc |
Sirna sequence-independent modification formats to reduce off-target phenotype effects in RNAI and stabilized forms thereof
|
|
AU2008306455C1
(en)
|
2007-10-03 |
2014-04-17 |
Quark Pharmaceuticals, Inc. |
Novel siRNA structures
|
|
CN101889087B
(zh)
*
|
2007-11-29 |
2013-04-03 |
苏州瑞博生物技术有限公司 |
一种干扰靶基因表达的复合分子及其制备方法
|
|
WO2009082817A1
(en)
|
2007-12-27 |
2009-07-09 |
Protiva Biotherapeutics, Inc. |
Silencing of polo-like kinase expression using interfering rna
|
|
US9309313B2
(en)
*
|
2008-01-09 |
2016-04-12 |
The Schepens Eye Research Institute, Inc. |
Therapeutic compositions for treatment of ocular inflammatory disorders
|
|
AU2009207922B2
(en)
|
2008-01-23 |
2015-05-14 |
Herlev Hospital |
YKL-40 as a general marker for non-specific disease
|
|
BRPI0910446A8
(pt)
*
|
2008-03-31 |
2016-07-26 |
Nat Inst Of Advanced Ind Scien |
rna modificado por lipídeo de filamento duplo tendo alto efeito de interferência de rna
|
|
JP2011516094A
(ja)
|
2008-04-15 |
2011-05-26 |
プロチバ バイオセラピューティクス インコーポレイティッド |
干渉ｒｎａを用いたｃｓｎ５遺伝子発現のサイレンシング方法
|
|
US8278287B2
(en)
|
2008-04-15 |
2012-10-02 |
Quark Pharmaceuticals Inc. |
siRNA compounds for inhibiting NRF2
|
|
AU2009238175C1
(en)
|
2008-04-15 |
2023-11-30 |
Arbutus Biopharma Corporation |
Novel lipid formulations for nucleic acid delivery
|
|
USRE48948E1
(en)
|
2008-04-18 |
2022-03-01 |
Warsaw Orthopedic, Inc. |
Clonidine compounds in a biodegradable polymer
|
|
WO2009131733A1
(en)
*
|
2008-04-21 |
2009-10-29 |
The Trustees Of Columbia University In The City Of New York |
Gab2 amplification in melanoma
|
|
JP5524189B2
(ja)
|
2008-06-06 |
2014-06-18 |
クォーク ファーマシューティカルズ インコーポレーティッド |
耳障害治療のための組成物および方法
|
|
US8309791B2
(en)
|
2008-07-16 |
2012-11-13 |
Recombinectics, Inc. |
Method for producing a transgenic pig using a hyper-methylated transposon
|
|
US8512944B2
(en)
|
2008-08-27 |
2013-08-20 |
Oncotherapy Science, Inc. |
PRMT1 for target genes of cancer therapy and diagnosis
|
|
NZ592241A
(en)
|
2008-09-15 |
2012-11-30 |
Herlev Hospital |
Ykl-40 as a marker for gastrointestinal cancers
|
|
JP2011251912A
(ja)
*
|
2008-09-22 |
2011-12-15 |
Gifu Prefecture Kenkyu Kaihatsu Zaidan |
マイクロｒｎａ―１４３誘導体を含有する医薬
|
|
US20100239632A1
(en)
|
2009-03-23 |
2010-09-23 |
Warsaw Orthopedic, Inc. |
Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
|
|
US20120128673A1
(en)
|
2009-05-20 |
2012-05-24 |
Schering Corporation |
Modulation of pilr receptors to treat microbial infections
|
|
ES2629339T3
(es)
|
2009-06-16 |
2017-08-08 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1
|
|
ES2613498T3
(es)
|
2009-07-01 |
2017-05-24 |
Protiva Biotherapeutics Inc. |
Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
|
|
WO2011011447A1
(en)
|
2009-07-20 |
2011-01-27 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing ebola virus gene expression
|
|
WO2011031600A1
(en)
|
2009-09-10 |
2011-03-17 |
Schering Corporation |
Use of il-33 antagonists to treat fibrotic disease
|
|
WO2011038160A2
(en)
|
2009-09-23 |
2011-03-31 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
|
DK2504435T3
(da)
|
2009-11-26 |
2019-12-09 |
Quark Pharmaceuticals Inc |
Sirna-forbindelser omfattende terminale substitutioner
|
|
US8691227B2
(en)
|
2009-12-17 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
|
|
WO2011084193A1
(en)
|
2010-01-07 |
2011-07-14 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide compounds comprising non-nucleotide overhangs
|
|
CN101787366B
(zh)
*
|
2010-03-04 |
2012-09-19 |
中国人民解放军军事医学科学院放射与辐射医学研究所 |
一种特异抑制Rab27B基因表达的DNA片段及其应用
|
|
RU2013102545A
(ru)
|
2010-07-28 |
2014-09-10 |
Алкон Ресерч, Лтд. |
Связывающая vegfa си-рнк и способы лечения in vivo
|
|
WO2012024170A2
(en)
|
2010-08-17 |
2012-02-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
WO2012027206A1
(en)
|
2010-08-24 |
2012-03-01 |
Merck Sharp & Dohme Corp. |
SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
|
|
EP2611933A1
(en)
*
|
2010-09-02 |
2013-07-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for the prognosis of the progression of cancer
|
|
EP2433644A1
(en)
|
2010-09-22 |
2012-03-28 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Breast cancer therapeutics
|
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
|
WO2012063894A1
(ja)
|
2010-11-12 |
2012-05-18 |
国立大学法人愛媛大学 |
マイクロｒｎａのアンチセンスオリゴヌクレオチドを含む組成物
|
|
CA2825894C
(en)
|
2011-02-02 |
2021-11-30 |
Amgen Inc. |
Prognosis of cancer using a circulating biomarker
|
|
BR112013033794A2
(pt)
*
|
2011-06-27 |
2019-09-24 |
Medimmune Llc |
uso de uma quantidade eficaz de uma composição, e, método para avaliar a presença, ausência ou quantidade de um biomarcador
|
|
HRP20181564T1
(hr)
|
2011-06-30 |
2018-11-30 |
Arrowhead Pharmaceuticals, Inc. |
Pripravci i postupci za inhibiciju ekspresije gena virusa hepatitisa b
|
|
WO2013010045A1
(en)
|
2011-07-12 |
2013-01-17 |
Biotime Inc. |
Novel methods and formulations for orthopedic cell therapy
|
|
EP2734531A1
(en)
|
2011-07-22 |
2014-05-28 |
Université de Strasbourg |
Phospholipid-detergent conjugates and uses thereof
|
|
EP2776450B1
(en)
*
|
2011-11-10 |
2018-04-04 |
Shire Human Genetic Therapies, Inc. |
Antisense oligonucleotide modulators of serotonin receptor 2c and uses thereof
|
|
CA2852127C
(en)
|
2011-11-11 |
2020-10-27 |
Duke University |
Combination drug therapy for the treatment of solid tumors
|
|
EP2780454A2
(en)
*
|
2011-11-18 |
2014-09-24 |
Alnylam Pharmaceuticals, Inc. |
Modified rnai agents
|
|
SG11201405157PA
(en)
|
2012-02-24 |
2014-10-30 |
Protiva Biotherapeutics Inc |
Trialkyl cationic lipids and methods of use thereof
|
|
US11180760B2
(en)
*
|
2012-03-09 |
2021-11-23 |
The Johns Hopkins University |
Identification of molecular pathways and methods of use thereof for treating retinal neurodegeneration and other neurodegenerative disorders
|
|
TWI480043B
(zh)
*
|
2012-05-01 |
2015-04-11 |
高雄醫學大學 |
用以治療塑化劑引發之雌激素受體陰性型乳癌的醫藥組成物
|
|
WO2013165816A2
(en)
|
2012-05-02 |
2013-11-07 |
Merck Sharp & Dohme Corp. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
|
US9434951B2
(en)
*
|
2012-05-22 |
2016-09-06 |
University Of Massachusetts |
Compositions and methods for decreasing leukocyte extravasation and vessel fluid leakage
|
|
US20150322428A1
(en)
*
|
2012-06-18 |
2015-11-12 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for improved cellular uptake of antisense compounds
|
|
US8980259B2
(en)
|
2012-07-20 |
2015-03-17 |
Novartis Ag |
Combination therapy
|
|
WO2014018375A1
(en)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
|
EP2700949A1
(en)
|
2012-08-24 |
2014-02-26 |
IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. |
Use of biliverdin reductase proteins as cancer marker
|
|
SG11201501385UA
(en)
|
2012-09-05 |
2015-03-30 |
Sylentis Sau |
Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions
|
|
GB201215857D0
(en)
|
2012-09-05 |
2012-10-24 |
Sylentis Sau |
siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
|
|
EP2892568B1
(en)
|
2012-09-06 |
2020-08-26 |
Health Research, Inc. |
Compositions and methods for inhibiting hypoxia induced damage
|
|
WO2014144666A2
(en)
*
|
2013-03-15 |
2014-09-18 |
The University Of Chicago |
Methods and compositions related to t-cell activity
|
|
KR102413498B1
(ko)
|
2013-04-20 |
2022-06-24 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
엑손 2-표적 U7snRNA 폴리뉴클레오티드 작제물의 재조합형 아데노 부속 바이러스 전달
|
|
WO2014197421A1
(en)
|
2013-06-05 |
2014-12-11 |
Biotime, Inc. |
Compositions and methods for induced tissue regeneration in mammalian species
|
|
CN105873568B
(zh)
|
2013-12-05 |
2019-10-08 |
赛伦斯治疗有限公司 |
用于肺特异性递送的工具
|
|
US11078462B2
(en)
|
2014-02-18 |
2021-08-03 |
ReCyte Therapeutics, Inc. |
Perivascular stromal cells from primate pluripotent stem cells
|
|
US10011837B2
(en)
|
2014-03-04 |
2018-07-03 |
Sylentis Sau |
SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions
|
|
KR102149572B1
(ko)
|
2014-05-19 |
2020-08-28 |
화이자 인코포레이티드 |
아시알로당단백질 수용체의 표적화제로서 치환된-6,8-다이옥사바이사이클로[3.2.1]옥탄-2,3-다이올 화합물
|
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
|
|
US10240127B2
(en)
|
2014-07-03 |
2019-03-26 |
ReCyte Therapeutics, Inc. |
Exosomes from clonal progenitor cells
|
|
US9790509B2
(en)
|
2014-07-18 |
2017-10-17 |
Oregon Health & Science University |
5′-triphosphate oligoribonucleotides
|
|
CA2957661A1
(en)
|
2014-08-09 |
2016-02-18 |
Kevin FLANIGAN |
Methods and materials for activating an internal ribosome entry site in exon 5 of the dmd gene
|
|
TWI710633B
(zh)
|
2014-11-10 |
2020-11-21 |
美商阿尼拉製藥公司 |
Ｂ型肝炎病毒（ＨＢＶ）ｉＲＮＡ組成物及其用途方法
|
|
EP3218395B1
(en)
|
2014-11-12 |
2022-01-05 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Treatment of hormonal disorders of growth
|
|
RU2563989C1
(ru)
*
|
2014-11-20 |
2015-09-27 |
Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) |
Композиция для подавления экспрессии гена цитокина интерлейкина-4
|
|
KR20180038465A
(ko)
|
2015-08-07 |
2018-04-16 |
애로우헤드 파마슈티컬스 인코포레이티드 |
Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법
|
|
CA3202332A1
(en)
|
2015-12-07 |
2017-06-15 |
Agex Therapeutics, Inc. |
Methods for the re-derivation of diverse pluripotent stem cell-derived brown fat cells
|
|
WO2017129763A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
|
|
WO2017173297A1
(en)
|
2016-04-01 |
2017-10-05 |
Avidity Biosciences Llc |
Beta-catenin nucleic acids and uses thereof
|
|
WO2017173304A1
(en)
|
2016-04-01 |
2017-10-05 |
Avidity Biosciences Llc |
Kras nucleic acids and uses thereof
|
|
MA45349A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques egfr et leurs utilisations
|
|
JP2019513371A
(ja)
|
2016-04-01 |
2019-05-30 |
アビディティー バイオサイエンシーズ エルエルシー |
核酸ポリペプチド組成物とその使用
|
|
TWI780046B
(zh)
*
|
2016-05-10 |
2022-10-11 |
國立大學法人東京醫科齒科大學 |
炎症促進因子表現抑制劑、其有效成分之篩選方法、對於該方法為有用之表現匣、診斷藥及診斷方法
|
|
US10036024B2
(en)
|
2016-06-03 |
2018-07-31 |
Purdue Research Foundation |
siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)
|
|
EP3269732A1
(en)
*
|
2016-07-11 |
2018-01-17 |
Rhemastem SRLS |
Therapeutic medium for the treatment of cancer
|
|
JOP20190015A1
(ar)
|
2016-08-04 |
2019-02-04 |
Arrowhead Pharmaceuticals Inc |
عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
|
|
EP3315125A1
(en)
|
2016-10-31 |
2018-05-02 |
Silence Therapeutics (London) Ltd |
Lipid nanoparticle formulation
|
|
EP4035659A1
(en)
|
2016-11-29 |
2022-08-03 |
PureTech LYT, Inc. |
Exosomes for delivery of therapeutic agents
|
|
EP3551641A4
(en)
|
2016-12-08 |
2021-01-13 |
University of Utah Research Foundation |
STAUFEN1 ACTIVE SUBSTANCES AND RELATED PROCEDURES
|
|
MX2019008199A
(es)
|
2017-01-06 |
2019-11-25 |
Avidity Biosciences Llc |
Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.
|
|
BR112019014282A2
(pt)
|
2017-01-10 |
2020-03-03 |
Arrowhead Pharmaceuticals, Inc. |
Agentes de rnai de antitripsina (aat) alfa-1, composições incluindo agentes de rnai de aat, e métodos de uso
|
|
US11324820B2
(en)
|
2017-04-18 |
2022-05-10 |
Alnylam Pharmaceuticals, Inc. |
Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
|
|
CA3060090A1
(en)
*
|
2017-04-19 |
2018-10-25 |
Bio-Path Holdings, Inc. |
P-ethoxy nucleic acids for igf-1r inhibition
|
|
AU2018255353B2
(en)
*
|
2017-04-19 |
2023-11-16 |
Bio-Path Holdings, Inc. |
P-ethoxy nucleic acids for IGF-1R inhibition
|
|
JP2020523027A
(ja)
|
2017-06-16 |
2020-08-06 |
イーエムベーアー−インスティテュート フュール モレクラレ バイオテクノロジー ゲゼルシャフト ミット ベシュレンクテル ハフツング |
血管オルガノイド、オルガノイドの製造及び使用方法
|
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
|
SG11202004097RA
(en)
*
|
2017-11-09 |
2020-06-29 |
Univ Nat Corp Tokyo Medical & Dental |
Inhibitor of the expression of cancer-promoting factors, screening method for active ingredient thereof, expression cassette useful in said method, diagnostic drug, and diagnostic method
|
|
JP7506601B2
(ja)
|
2017-12-06 |
2024-06-26 |
アビディティー バイオサイエンシーズ，インク． |
筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法
|
|
US20210032334A1
(en)
*
|
2018-02-28 |
2021-02-04 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
|
|
WO2019178364A2
(en)
*
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
US11946046B2
(en)
|
2018-06-14 |
2024-04-02 |
University Of Utah Research Foundation |
Staufen1 regulating agents and associated methods
|
|
CN108977445B
(zh)
*
|
2018-06-29 |
2021-05-25 |
山东农业大学 |
拟南芥microRNA400在调控植物耐镉性中的应用
|
|
WO2020011653A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting kynu
|
|
WO2020011743A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mafb
|
|
US10857174B2
(en)
|
2018-07-27 |
2020-12-08 |
United States Government As Represented By The Department Of Veterans Affairs |
Morpholino oligonucleotides useful in cancer treatment
|
|
US12370264B1
(en)
|
2018-08-02 |
2025-07-29 |
Dyne Therapeutics, Inc. |
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
EP3829595A4
(en)
|
2018-08-02 |
2022-08-24 |
Dyne Therapeutics, Inc. |
MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES
|
|
US11168141B2
(en)
|
2018-08-02 |
2021-11-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
US20210292768A1
(en)
*
|
2018-08-08 |
2021-09-23 |
Arcturus Therapeutics, Inc. |
Compositions and agents against nonalcoholic steatohepatitis
|
|
CA3106701A1
(en)
|
2018-08-13 |
2020-02-20 |
Alnylam Pharmaceuticals, Inc. |
Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof
|
|
KR102097794B1
(ko)
*
|
2018-09-17 |
2020-04-06 |
차의과학대학교 산학협력단 |
신규한 miRNA smR-167 및 폐암 예방 또는 치료를 위한 이의 용도
|
|
WO2020117715A1
(en)
|
2018-12-03 |
2020-06-11 |
Board Of Regents, The University Of Texas System |
Oligo-benzamide analogs and their use in cancer treatment
|
|
IL312067B2
(en)
|
2018-12-21 |
2025-08-01 |
Avidity Biosciences Inc |
Anti-transferrin receptor antibodies and uses thereof
|
|
US12497615B2
(en)
|
2019-04-25 |
2025-12-16 |
Avidity Biosciences, Inc. |
Nucleic acid compositions and methods of multi-exon skipping
|
|
WO2020225779A1
(en)
|
2019-05-09 |
2020-11-12 |
Istituto Pasteur Italia - Fondazione Cenci Bolognetti |
Rig-i agonists for cancer treatment and immunotherapy
|
|
MX2021015003A
(es)
|
2019-06-06 |
2022-01-24 |
Arrowhead Pharmaceuticals Inc |
Metodos para el tratamiento de la deficiencia de alfa-1 antitripsina (aatd).
|
|
JP7709981B2
(ja)
|
2020-03-17 |
2025-07-17 |
ジェネヴァント サイエンシズ ゲーエムベーハー |
肝星細胞への治療薬の脂質ナノ粒子送達のためのカチオン性脂質
|
|
US11555190B2
(en)
|
2020-03-19 |
2023-01-17 |
Avidity Biosciences, Inc. |
Compositions and methods of treating Facioscapulohumeral muscular dystrophy
|
|
AU2021241682B2
(en)
|
2020-03-27 |
2026-02-12 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle dystrophy
|
|
EP4164656A4
(en)
*
|
2020-06-11 |
2025-10-22 |
Ionis Pharmaceuticals Inc |
COMPOUNDS AND METHODS FOR REDUCING MSH3 EXPRESSION
|
|
IL299827B1
(en)
|
2020-07-15 |
2026-04-01 |
Cerebral Therapeutics Inc |
A medical system that includes two access ports
|
|
DE102020128677A1
(de)
*
|
2020-10-30 |
2022-05-05 |
Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen, Körperschaft des öffentlichen Rechts |
Ein neues Target zur Behandlung der Nierenfibrose
|
|
AU2021403156A1
(en)
|
2020-12-18 |
2023-07-13 |
Genevant Sciences Gmbh |
Peg lipids and lipid nanoparticles
|
|
AU2022212580A1
(en)
*
|
2021-01-30 |
2023-07-27 |
E-Therapeutics Plc |
Nucleic acids containing abasic nucleotides
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
MX2024003266A
(es)
|
2021-09-16 |
2024-04-03 |
Avidity Biosciences Inc |
Composiciones y metodos de tratamiento de la distrofia muscular facioescapulohumeral.
|
|
IL312811A
(en)
|
2021-11-16 |
2024-07-01 |
Shanghai Argo Biopharmaceutical Co Ltd |
Composition and method for inhibiting angiotensinogen (agt) protein expression
|
|
CA3250180A1
(en)
|
2022-01-31 |
2023-08-03 |
Genevant Sciences Gmbh |
IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES
|
|
CN118900701A
(zh)
|
2022-01-31 |
2024-11-05 |
盖纳万科学有限公司 |
聚(烷基噁唑啉)-脂质缀合物及含有聚(烷基噁唑啉)-脂质缀合物的脂质颗粒
|
|
US12605537B2
(en)
|
2022-02-15 |
2026-04-21 |
Biogen Ma Inc. |
Implantable medical device for use with or having recording electrode
|
|
KR20240163743A
(ko)
|
2022-03-28 |
2024-11-19 |
엠피리코 인크. |
변형된 올리고뉴클레오티드
|
|
US12071621B2
(en)
|
2022-04-05 |
2024-08-27 |
Avidity Biosciences, Inc. |
Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
|
|
US20250339553A1
(en)
|
2022-04-15 |
2025-11-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating myotonic dystrophy
|
|
WO2024159113A1
(en)
*
|
2023-01-27 |
2024-08-02 |
The Methodist Hospital |
Modulators of alternative polyadenylation and methods of use thereof
|
|
WO2024215814A2
(en)
*
|
2023-04-10 |
2024-10-17 |
Anand Rene |
Methods and pharmaceutical compositions for treating aging
|
|
WO2025052278A1
(en)
|
2023-09-05 |
2025-03-13 |
Genevant Sciences Gmbh |
Pyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
|
|
WO2025133951A1
(en)
|
2023-12-21 |
2025-06-26 |
Genevant Sciences Gmbh |
Ionizable lipids suitable for lipid nanoparticles
|
|
WO2026022656A2
(en)
|
2024-07-22 |
2026-01-29 |
Genevant Sciences Gmbh |
Lipid particle formulations with permanently charged cationic lipids
|
|
WO2026022677A1
(en)
|
2024-07-22 |
2026-01-29 |
Genevant Sciences Gmbh |
Permanently charged cationic lipids
|